Research infrastructures (RIs) operate in complex innovation ecosystems where industry plays an increasingly important role. Pan-EU initiatives, such as the Innovation Union or the European Strategy Forum on Research Infrastructures, revolutionise the way public and private sectors work together, and help to create structural frameworks which are needed to foster such collaborations. While initiatives of this type play a crucial role in enabling industry to become a full partner of research infrastructures whether it is as a user, a supplier, or a co-creator, they do not fully utilise or engage Industrial Liaison and Contact Officers (ILOs/ICOs) which could have a central role in boosting the RI-industry partnerships. To address this gap, ENRIITC will build a permanent pan-European network of ILOs and ICOs. This will be done in a community-driven, cross-functional, cross-sectoral, multiplier-based way which will be inclusive and enable all interested parties to actively participate. By supporting the establishment of strategic, cross-border partnerships between industry and research infrastructures, ENRIITC will enable win-win results for all parties. With a timeline of 36 months, 11 partners from seven countries, and a strong support from 61 Associates from around Europe, ENRIITC will 1) establish a sustainable European network of ILOs and ICOs which enables mutual learning, 2) map collaboration potential between research infrastructures and industry, 3) develop and refine strategies and best practices to foster these collaborations, 4) raise awareness among industry for collaboration opportunities at research infrastructures, and demonstrate impact. The consortium and Associates will jointly balance the need for expertise from diverse scientific areas, combine it with practical insights from establishing relations with various industries operating in different sectors and geographical contexts, and propagate it among their networks.

The ERA-NET Cofund BlueBio will act to unlock the potential of aquatic bio-resources to create jobs, economic growth and provide food, nutrition and bio-based products and services. Thus, paving the way for a sustainable and competitive Blue Bioeconomy in Europe. The goal is to identify new and improve existing ways of bringing bio-based products and services to the market and find new ways of creating value in the Blue bioeconomy. The objectives of BlueBio are to establish a coordinated R&D funding scheme that will strengthen Europe’s position in this complex economic field in a global market. This will primarily be achieved by engaging funding agencies to implement a co-funded call focusing on Blue Knowledge and technological developments to respond to needs and gaps for R&I. The consortium has committed budgets making a strong co-funded call leveraging well the Commission's requests. BlueBio builds upon the networks, achievements and strategies obtained in the COFASP and ERA-MBT ERA-NETs and JPI Oceans, and will leverage the JPI Oceans role as a coordination platform. The consortium aims to implement 2-4 additional calls, developed through stakeholder engagement, and identifying new funding initiatives. BlueBio will implement a range of related activities which can add value to the cofounded projects and better address the impact of R&I projects. BlueBio will enhance valorisation from the actors in the Blue Bioeconomy sector, identify and address R&I needs of industry and society. Communications activities will support BlueBio and the funded projects to realise tangible impacts. Emphasis will be placed on the creation of pre-commercial outputs aimed at accelerating commercialisation and competitive deployment. BlueBio's directions and legacy will be informed by strategic forward-looking processes involving all stakeholders in identifying needs and gaps along the value chains.

Europe is facing major economic challenges that require an ambitious economic policy for the 21st century. The EU has set out its vision for Europe's social market economy in the Europe 2020 strategy, which aims at confronting our structural weaknesses through progress in three mutually reinforcing priorities : • smart growth, based on knowledge and innovation, • sustainable growth, promoting a more resource efficient, greener and competitive economy, • inclusive growth, fostering a high employment economy delivering economic, social and territorial cohesion. MANUNET III, as a continuation of MANUNET II, is aligned with the European priorities and pretends to create a smart sustainable growth in the European manufacturing sector by coordinating the research and innovation efforts in the field of advanced manufacturing with a special focus in the key areas of new production processes, adaptive manufacturing systems and technologies for the factory of the future. The project will also reinforce the territorial cohesion through an extended collaboration network. The consortium pretends to respond to the actual economic crisis by promoting the transnational research, innovation and entrepreneurship in the industrial sector, especially in the SMEs, which are the backbone of Europe's economy. Through this strategic and integrated approach to innovation in advanced manufacturing, MANUNET III pretends to maximise European, national and regional research and innovation potential.

Nanomedicine is the application of nanotechnology to medicine and healthcare. The field takes advantage of the physical, chemical and biological properties of materials at the nanometer scale to be used for a better understanding of the biological mechanisms of diseases at the molecular level, leading to new targets for earlier and more precise diagnostics and therapeutics. Nanomedicine, rated among the six most promising Key Enabling Technologies, is one of the most important emerging areas of health research expected to contribute to one of the strategic challenges that Europe has to face in the future: Provide effective and affordable health care and assure the wellbeing of an increasingly aged population. EuroNanoMed III (ENM III) builds on the foundations of ENM I & II, which launched 7 successful joint calls for proposals since 2009, funded 51 transnational research projects involving 269 partners from 25 countries/regions, and allocated € 45,5 million to research projects from ENM funding agencies. ENM III consortium, reinforced with 12 new partners from Europe, Canada and Taiwan, is committed to fostering the competiveness of European nanomedicine actors taking into account recent changes in the landscape and new stakeholders and challenges, as identified in the SRIA in nanomedicine. The first joint call for proposals will be co-funded by ENM III partners and the EC. After the co-funded call, three additional joint transnational calls will be organized and strategic activities will be accomplished in collaboration with key initiatives in the field. ENM III actions focus on translatability of project results to clinical and industry needs.